31 results about "Metabolic profile" patented technology

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and / or lab test data collected for the patient. The platform encodes the biosignals into a vector representation and inputs the vector representation into a patient-specific metabolic model to determine a metabolic state of the patient at a conclusion of the current time period. The patient-specific metabolic model comprises a set of parameter values determined based on labels assigned to the previous metabolic states and a function representing one or more effects of the plurality of biosignals of the personalized metabolic profile. The platform compares the determined metabolic state of the patient to a threshold metabolic state representing a target metabolism. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve the determined metabolic state to the functional metabolic state.

The invention discloses a rapid detection method for bloodstream infection pathogenic bacteria based on a rapid mass spectrometry technology, and belongs to the technical field of medical detection. Analyzing the metabolic gas of the blood flow infected pathogenic bacteria by using UVP-TOFMS to obtain a pathogenic bacteria metabolic profile spectrogram; preprocessing the obtained pathogenic bacterium metabolism profile spectrogram data; integrating the preprocessed pathogenic bacterium metabolism profile spectrogram data by using a stacking algorithm, and constructing a pathogenic bacterium identification model; evaluating the effectiveness of the pathogenic bacterium identification model on a training set and a test set through accuracy, precision, a confusion matrix and a subject operation curve; and comparing and screening characteristic metabolic markers of the pathogenic bacteria by combining the importance and significance of model characteristics, and indicating the types of the pathogenic bacteria. The method does not need sample pretreatment, is simple and convenient to operate, short in detection time (20 seconds per sample), high in accuracy and suitable for clinical popularization, and provides technical support for early diagnosis and treatment of bloodstream infection.

The invention relates to a method of diagnosing a subtype of autism spectrum disorder (ASD), so called ASD Phenotype 1, by assessing the energy production capacity of patient specific cell lines in presence of various carbon sources of energy and metabolic factors or by assessing the changes in energy production capacity or lack thereof after administration of an Nrf2-inhibitor.

The invention provides a pulmonary nodule targeting food and medicine homologous composition based on metabonomics screening and application thereof. By analyzing a pulmonary nodule specific metabolic profile, active components, namely platycodin D, mogroside V, oyster active peptide and fermented cordycepin, which can cooperatively regulate and control an arachidonic acid inflammation pathway, a glutathione antioxidant pathway and a tricarboxylic acid cycle energy pathway are reversely screened out. Animal experiments prove that the composition can reduce the volume of pulmonary nodules by 58.3%, human body application shows that the nodules of 76.7% of subjects are reduced, and liver and kidney toxicity is avoided. The composition can be prepared into tablets, capsules and other dosage forms, can be used as functional food or adjuvant therapy drugs for high risk groups of pulmonary nodules, and realizes accurate nutrition intervention.

This invention discloses a pharmaceutical composition for treating asthenospermia by activating the Nrf2 / HO-1 / GPx4 pathway and its application. The pharmaceutical composition comprises taurine and geranium as active ingredients, wherein the mass ratio of taurine to geranium is 3-5:1. The pharmaceutical composition of this invention can synergistically activate the Nrf2 / HO-1 / GPx4 antioxidant signaling pathway, upregulate the expression of downstream antioxidant enzymes GPx4 and HO-1, inhibit lipid peroxidation, protect sperm mitochondrial function, and simultaneously improve the microenvironmental metabolic profile of the epididymis—the site of sperm maturation—thereby enhancing sperm motility. The pharmaceutical composition provided by this invention can be used to prepare a treatment for asthenospermia, particularly oxidative stress-induced asthenospermia.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and / or lab test data collected for the patient. The platform receives patient data recorded during the current time period comprising food items consumed, medications taken, and symptoms experienced by the patient. The platform implements a machine-learned metabolic model to determine a metabolic state of the patient at a conclusion of the current time period by comparing a true representation of the metabolic state and a prediction of the metabolic state. The true representation and the prediction are determined based on the recorded biosignals and the recorded patient data, respectively. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve their metabolic state and provides the patient-specific treatment recommendation to the patient device for display to the patient.

This invention relates to a method for identifying and detecting urinary biomarkers of whole-grain wheat intake. These biomarkers include glycine conjugates of 3,5-dihydroxybenzoic acid, sulfate conjugates of o-aminophenol, sulfate conjugates of 2-acetaminophen, sulfate conjugates of 3,5-dihydroxyphenylvaleric acid, glucuronic acid conjugates of o-aminophenol, or glucuronic acid conjugates of 2-acetaminophen. The invention also relates to a high-throughput screening method for urinary biomarkers of whole-grain wheat intake. A whole-grain wheat dietary intervention experiment was designed, and through comparative analysis of human urinary metabolic profiles, non-targeted metabolomics technology was used to screen for urinary metabolic biomarkers of whole-grain wheat, providing a method for accurately assessing whole-grain wheat intake.

The application belongs to the technical field of biological medicine, and discloses application of NP in preparation of a preparation for regulating metabolism of the intestines of senile type 2 diabetes. The NP is formed by hydrogen bond combination of a peptide from soft-shelled turtle eggs with naringenin in a mass ratio of 100:1, and the mass of the peptide is less than 3 kDa; the preparation is used for regulating phenotype-related metabolic modules and intestinal micro-ecological-related metabolic modules, remodeling the intestinal metabolic regulation network taking differential metabolites as a bridge, and thus systemically improving metabolic disorders related to senile type 2 diabetes. It is found that NP intervention can obviously correct abnormal total metabolic profiles of feces of senile type 2 diabetes mice, and make the disease type metabolic profile shift to a new steady state of intervention type. Non-targeted metabolomics analysis by LC-MS / MS shows that the overall metabolic profile of the high-dose NP group is closer to that of the classic hypoglycemic drug metformin group, indicating that NP has a significant metabolic remodeling capacity.

There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and / or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and / or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.

According to the compound anti-tumor screening method provided by the invention, a cell metabolism phenotype model, namely a D-lactic acid cell model, is established, and a compound capable of reducing abnormal change of metabolite content induced by D-lactic acid is screened by taking a cell metabolism profile as a detection index. According to the method, a progressive evaluation system from in-vitro metabonomics screening to in-vivo pharmacodynamic verification is adopted, compounds influencing the change of the metabolite content of cells are effectively recognized and evaluated, the limitation of traditional tumor drug screening is broken through, the cell metabolism change caused by D-lactic acid is focused, the targeting property and reliability of anti-cancer drug development are remarkably improved, and the method is suitable for clinical application. And an innovative technical path is provided for treating tumors related to abnormal metabolism.

In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and / or lab test data collected for the patient. The platform encodes the biosignals into a vector representation and inputs the vector representation into a patient-specific metabolic model to determine a metabolic state of the patient at a conclusion of the current time period. The patient-specific metabolic model comprises a set of parameter values determined based on labels assigned to the previous metabolic states and a function representing one or more effects of the plurality of biosignals of the personalized metabolic profile. The platform compares the determined metabolic state of the patient to a threshold metabolic state representing a target metabolism. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve the determined metabolic state to the functional metabolic state.

The invention discloses a group of diagnosis, typing and prognostic markers for children Langerhans cell histocytosis, and belongs to the technical field of disease diagnosis. In the invention, an overall metabolic profile of bone marrow aspirates (BMA) of 34 children LCH patients is analyzed, and the patients are divided into three subtypes: single system diseases (SS), multi-system diseases (MS-RO-) without dangerous organ tiredness and multi-system diseases (MS-RO +) with dangerous organ tiredness. The metabonomics characteristics of children diagnosed as LCH are described, the metabolic characteristics of a multi-system LCH (MS-RO +) group with dangerous organs being tired before and after treatment are comprehensively researched, and important metabolic markers for molecular diagnosis, subtype classification, treatment evaluation and prognosis are provided for children patients suffering from LCH, especially high-risk LCH.

The invention relates to a method for noninvasively evaluating age-dependent metabolic characteristics of mouse oocytes. The method comprises the following steps: S1, collecting oocytes of mice at different month ages; s2, treating the oocytes to obtain a sample capable of being used for spontaneous Raman spectroscopy and imaging; s3, performing spontaneous Raman spectroscopy and imaging of different oocytes; s4, processing and analyzing Raman spectrum data; s5, processing and analyzing two-dimensional and three-dimensional Raman imaging; s6, analyzing morphological and spectral characteristics of oocytes of mice of different age groups; and S7: determining the specific age-related change of the lipid content and distribution, the cytochrome c level and the metabolic profile in the mouse oocytes. Compared with the prior art, the method has the advantages that the metabolic change of the oocytes of mice with different maternal ages is analyzed by Raman spectrum for the first time, the age-dependent distribution change of lipid and cytochrome c is revealed through high-resolution subcellular mapping, and a new research scheme is provided for the biochemical mechanism of oocyte senescence.

In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

A pharmaceutical composition comprises a muscarinic agonist and a pharmacokinetic (PK) modifier that changes the metabolic profile the muscarinic agonist. The pharmaceutical composition may be used for the treatment of a neurological disorder or condition in a subject.

The invention relates to a detection method for establishing a brucella infected serum metabolic map based on laser dissociation mass spectrometry, which comprises the following steps: step 1, performing metabolism detection on serum samples of brucellosis patients and healthy volunteers by using an iron nanoparticle-assisted laser desorption ionization mass spectrometry technology to obtain a serum metabolism fingerprint map; step 2, carrying out various model training on a serum sample by adopting a machine learning algorithm on the serum metabolism fingerprint spectrogram obtained in the step 1, evaluating various models through a cross validation method, and screening a final diagnosis model according to a validation result; and step 3, diagnosing serum samples of brucellosis patients and healthy volunteers according to the diagnosis model in the step 2, and screening metabolic biomarkers in the serum samples according to a diagnosis result. According to the marker combination, the detection process is rapid and simple, the result is accurate and reliable, and the screened metabolic biomarker can be used for diagnosing brucellosis.

The invention relates to a neonatal genetic disease gene and metabolite combined screening method, system and equipment, and the method comprises the steps: carrying out the rapid detection of a plurality of metabolites on a neonatal biological sample, and obtaining metabolic spectrogram data; comparing the metabolic spectrogram data with a metabolic phenotype-genotype associated knowledge base, and automatically identifying an abnormal metabolic phenotype meeting a preset condition; in response to the identified abnormal metabolic phenotype, automatically triggering gene analysis of a specific gene corresponding to the target genetic disease in the same biological sample; based on the abnormal metabolic phenotype and the gene analysis result of the specific gene, a combined screening report is generated, so that accurate and efficient source tracing from a non-specific metabolic disorder index to a specific pathogenic gene source is achieved, and the purpose of providing an integrated screening and auxiliary diagnosis solution for neonatal genetic diseases is achieved.

A patient health management platform implements a machine-learned metabolic model to generate a prediction of a patient's blood pressure. The platform implements a short-term prediction model to generate a daily prediction of the patient's blood pressure based on nutrition data reported by the patient and sensor data and lab test data collected for the patient. The platform implements a long-term prediction model generate a prediction of the patient's blood pressure during an extended time period based on sensor data and lab test data collected for the patient. Using the short-term prediction model, the long-term prediction model, or both, the patient health management platform generates predictions of the patient's diastolic and systolic blood pressure and updates a digital twin of the patient's metabolic profile.

A patient health management platform implements a machine-learned metabolic model to generate a prediction of a patient's glucose level. The platform implements a short-term prediction model to generate a daily prediction of the patient's glucose level based on nutrition data reported by the patient and sensor data and lab test data collected for the patient. The platform implements a long-term prediction model generate a prediction of the patient's glucose level during an extended time period based on sensor data and lab test data collected for the patient. Using the short-term prediction model, the long-term prediction model, or both, the patient health management platform generates predictions of the patient's glucose level and updates a digital twin of the patient's metabolic profile.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and / or lab test data collected for the patient. The platform receives patient data recorded during the current time period comprising food items consumed, medications taken, and symptoms experienced by the patient. The platform implements a machine-learned metabolic model to determine a metabolic state of the patient at a conclusion of the current time period by comparing a true representation of the metabolic state and a prediction of the metabolic state. The true representation and the prediction are determined based on the recorded biosignals and the recorded patient data, respectively. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve their metabolic state and provides the patient-specific treatment recommendation to the patient device for display to the patient.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of androstenediol, oxtenedioate, digydrouracil, heptanoylglutamine, pregnenetriol, sulfate, heptenoylglutamine, hexanoylglutamine, guanine, methylhexanoylglutamine, hexanoylglycine, hexenoylglycine, spermidine, diacetylspermine, acisoga and combinations thereof; and producing a metabolic profile for the metabolite.

Provided herein are methods and systems for determining and measuring Cannabaceae- based treatments through analysis of biological samples. The methods comprise obtaining samples, quantifying metabolites, and generating a database of metabolic profiles and treatment responses. Statistical analysis calculates z-scores to assess physiological deviations, and machine learning algorithms predict optimal dosages of Cannabaceae-derived molecules to normalize metabolite levels. The system includes modules for sample collection, data management, statistical analysis, diagnostics, and personalized treatment recommendations, offering real-time adjustments to treatments based on individual metabolic responses.

The invention provides an application of catechin as a diagnostic target in preparation of a uremic pruritus diagnostic product, and relates to the technical field of biomedicine, the technical key points are as follows: in the application, uremic pruritus micromolecular substances are found by using serum of a uremic patient to carry out a non-targeted metabonomics technology, and generally, the application of catechin as a diagnostic target in preparation of a uremic pruritus diagnostic product has a good clinical application prospect. Metabolic profiles of serum from human subjects diagnosed with uremic pruritus, including pre-dialysis pruritus, post-dialysis transient remission, and non-remission of pre-dialysis pruritus, are determined. Metabolic profiles from the two groups of biological samples are compared, and differential molecules exist in the metabolic profiles from the two groups of patients suffering from uremic pruritus. According to the invention, through non-targeted metabonomics, a significantly different molecule catechin which the pruritus of a uremia patient is not relieved before and after dialysis and the pruritus is temporarily relieved after dialysis is screened out, the catechin is injected into the cheek part of a normal mouse, and the pruritus conditions of the two mouse models are detected through behavioristics. And the evidence of mouse pruritus caused by the catechin is provided through a verification test.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, alio-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

The invention relates to a diagnostic index for hypertension grading and application thereof, and belongs to the technical field of biology. By screening catecholamine and hormone metabolic profiles in blood plasma of hypertensive patients and analyzing the relationship between different hypertension grading and cardiovascular adverse events and catecholamine and hormone levels, the corticotin level can be used as a diagnostic index of hypertension grading. The invention breaks through the traditional few index detection limitation, comprehensively detects a series of catecholamines and metabolites thereof, covers novel and less concerned methylation or oxidation modified derivatives and the like, deeply captures metabolic pathway changes, finds a new metabolic biomarker corticosin, fills up the blank of metabolite detection, and provides more molecular basis for accurate diagnosis; a more accurate and comprehensive diagnosis method is established, and excessive diagnosis of the secondary hypertension and missed diagnosis of the secondary hypertension are reduced, so that a patient can obtain targeted treatment.

The invention provides a plasma metabolism marker for kidney cancer diagnosis and application thereof, and belongs to the technical field of disease diagnosis. According to the invention, through comprehensive analysis and comparison of metabolic profiles of healthy people, kidney benign disease patients and kidney cancer patients, a group of metabolic marker combination with high specificity and significant difference is screened out, and the metabolic marker combination comprises 14 metabolic markers. As an end product of cell metabolic activity, the metabolic marker can more directly and sensitively reflect the abnormal metabolic state of tumor cells, so that early accurate recognition of kidney cancer and precancerous lesions is realized, the sensitivity of early diagnosis is remarkably improved, and the current clinical dilemma of'late stage once found 'is fundamentally reversed. The strategy is expected to greatly improve the survival rate and life quality of patients with kidney cancer, and a brand new path is provided for promoting precise medical treatment of kidney cancer.

The invention relates to the technical field of detection rating, in particular to an electronic nose-based fast and lossless beef carcass rating method, which comprises the following steps of: implementing directional adsorption sampling on a target carcass through a multi-directional adsorption probe of an electronic nose, and synchronously recording the distribution tensor of volatile substances in a time-space dimension; inputting the distribution tensor into competitive adsorption compensation, carrying out molecular adsorption decoupling calculation, and outputting a correction concentration matrix of each independent volatile substance; coupling the correction concentration matrix with an ATP degradation kinetic model in real time, generating a metabolism characteristic spectrum through a time-varying concentration compensation algorithm, and inputting the metabolism characteristic spectrum into a grading neural network subjected to muscle texture optimization to output a final grading result; according to the method, through time-varying compensation and ATP degradation dynamic integral correction, the metabolic dynamics after slaughter are tracked in real time, the limitation that a traditional static rating model ignores the metabolic hysteresis effect is broken through, and the final grading result still has high consistency and reliability under the conditions of environment change, slaughter batch difference and the like.

The invention discloses a method for detecting a urine steroid hormone metabolic profile by solid phase extraction-ultra-high performance liquid chromatography-tandem mass spectrometry. The method comprises the following steps: S1, preparing an internal standard stock solution and a target analyte standard stock solution; s2, pretreatment of a to-be-detected urine sample: S2.1, enzymolysis: taking the to-be-detected urine, adding the internal standard stock solution and the enzymolysis application solution, mixing, and incubating, so that uronide is fully hydrolyzed; s2.2, solid-phase extraction, separation and purification; s2.3, carrying out multi-step solvent distribution and redissolution; s2.4, filtering the reconstitution fluid through a filter membrane; s3, urine sample analysis: performing high performance liquid chromatography-triple quadrupole tandem mass spectrometry determination on the filtered reconstitution fluid; s4, drawing a standard curve; and S5, data analysis: performing internal standard method quantification on the analyte according to the ratio of the target peak area to the internal standard peak area. The detection method disclosed by the invention is high in accuracy, high in sensitivity and good in result reproducibility.